Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies
Go back to Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies| Gilead Sciences (NASDAQ: GILD) | Delayed: 156.04 -1.15 (0.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $157.19 | 52 Week High | $108.63 | |||
| Open | $156.47 | 52 Week Low | $71.39 | |||
| Day High | $157.65 | P/E | 86.21 | |||
| Day Low | $155.76 | EPS | $1.81 | |||
| Volume | 6,070,932 | |||||
| (NYSE: RCUS) | Delayed: 18.54 -0.82 (4.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $19.36 | 52 Week High | $ | |||
| Open | $19.02 | 52 Week Low | $ | |||
| Day High | $19.09 | P/E | N/A | |||
| Day Low | $18.43 | EPS | $ | |||
| Volume | 5,925,219 | |||||



